Dietary Nitrate, Vascular Function and Inflammation
Effects of Dietary Nitrate on Vascular Function, Blood Pressure, the Oral Microbiome, and Biomarkers of Systemic Inflammation in Hypertensive Older Adults: a Randomized, Placebo-controlled Crossover Study
1 other identifier
interventional
20
1 country
2
Brief Summary
The risk for cardiovascular diseases (CVD) increases with advancing age. Developing effective lifestyle-based strategies to promote, preserve or restore cardiovascular health with aging is a high priority. The overall aim of this clinical research is to investigate the innovative concept that an increased intake of dietary nitrate (through beetroot juice) could be a feasible adjuvant therapy to treat elevated blood pressure and improve blood vessel function in older adults. Inorganic dietary nitrate, found in beetroot and green leafy vegetables, is a source of nitric oxide (NO), a signaling molecule that is important for cardiovascular health. NO is also produced in the human body, but the body's production and availability of NO decrease during ageing and CVD. The declined NO availability is associated with impaired blood vessel function, unresolved inflammatory responses, and an increased CVD risk. Dietary nitrate is an additional NO source. Following the intake of nitrate, NO is produced in a pathway that involves commensal bacteria in the mouth. So far, little is known about whether dietary nitrate improves cardiovascular health in older populations with high blood pressure. The aim of this randomized, placebo-controlled crossover study is to investigate whether the daily intake of nitrate-rich beetroot juice over four weeks translates into improved cardiovascular health-related outcomes in older adults with treated mild high blood pressure. Men and women, between the ages of 55 and 70 years, who have been diagnosed with grade 1 high blood pressure and who are taking two or more blood-pressure lowering medications will be recruited. The study will investigate whether the increased dietary nitrate intake further lowers blood pressure and improves blood vessel function. A specific aim is to examine whether the nitrate intake results in favorable changes in the oral bacteria community and the systemic inflammatory status, and whether these changes correlate with cardiovascular-related outcomes. This research will offer information on the value of dietary nitrate to counteract chronic inflammation, the latter of which plays a role in developing or worsening cardiovascular disorders, such as high blood pressure. The expected results of this study will provide important new evidence of whether nitrate-rich beetroot juice could be a key component of therapeutic interventions to improve cardiovascular health in individuals with high blood pressure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable hypertension
Started Jan 2021
Typical duration for not_applicable hypertension
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 29, 2020
CompletedFirst Posted
Study publicly available on registry
October 14, 2020
CompletedStudy Start
First participant enrolled
January 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 28, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 28, 2023
CompletedMay 10, 2023
May 1, 2023
2.2 years
September 29, 2020
May 9, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Change in forearm blood flow (FBF) response to acetylcholine
Vascular function
Change from baseline FBF at 4 weeks of the HI-NI intervention
Change in forearm blood flow (FBF) response to acetylcholine
Vascular function
Change from baseline FBF at 4 weeks of the LO-NI intervention
Change in 24 hour-ambulatory systolic blood pressure
Blood pressure
Change from baseline 24 hour-ambulatory systolic blood pressure at 4 weeks of the HI-NI intervention
Change in 24 hour-ambulatory systolic blood pressure
Blood pressure
Change from baseline 24 hour-ambulatory systolic blood pressure at 4 weeks of the LO-NI intervention
Secondary Outcomes (4)
Change in granulocyte CD11b expression
Change from baseline granulocyte CD11b expression at 4 weeks of the HI-NI intervention
Change in granulocyte CD11b expression
Change from baseline granulocyte CD11b expression at 4 weeks of the LO-NI intervention
Change in forearm blood flow (FBF) response to glyceryltrinitrate
Change from baseline FBF at 4 weeks of the HI-NI intervention
Change in forearm blood flow (FBF) response to glyceryltrinitrate
Change from baseline FBF at 4 weeks of the LO-NI intervention
Other Outcomes (8)
Change in clinical blood pressure
Change from baseline clinical blood pressure at 4 weeks of the HI-NI intervention
Change in clinical blood pressure
Change from baseline clinical blood pressure at 4 weeks of the LO-NI intervention
Change in plasma nitrate and nitrite
Change from baseline plasma nitrate and nitrite at 4 weeks of the HI-NI intervention
- +5 more other outcomes
Study Arms (2)
High-nitrate (HI-NI) intervention
ACTIVE COMPARATORThe 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.
Low-nitrate (LO-NI) intervention
PLACEBO COMPARATORThe placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.
Interventions
The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.
Eligibility Criteria
You may qualify if:
- Ambulant male and females between 55 and 75 years of age, inclusive
- Resting systolic blood pressure between 130 and 170 mmHg, inclusive
- Written informed consent
You may not qualify if:
- Diastolic blood pressure \>110 mmHg
- Type 1 or 2 diabetes mellitus or fasting glucose \>7.0 mmol/L
- Any evidence of acute or chronic disease such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) \<50 ml/min)), or cancer which is not in remission
- Consumption of ≥5 serves of vegetables per day
- Consumption of a diet estimated to contain \>200 mg/d of nitrate
- Being vegan or vegetarian
- BMI ≥35 kg/m2 or \<18.5 kg/m2
- Use of nitric oxide donors, organic nitrites/nitrates, sildenafil and related drugs, anti-coagulation, non-steroidal anti-inflammatory or statin-related drugs
- Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouth wash for a period of 4 weeks before randomisation will be included)
- Use of antibiotics (within previous 2 months)
- A change in drug therapy likely to influence blood pressure or major secondary outcomes within the previous month, or the likelihood that drug therapy would change during the study
- Current or recent (within previous 3 months) engagement in regular structured exercise training (more than 2 hours of moderate to more intense exercise per week)
- Current or recent (within previous 6 months) loss or gain of \>6% of body weight
- Current or recent (\<12 months) regular smoking of \>5 cigarettes/day
- Alcohol intake \>140 g per week for women or \>210 g per week for men and/or binge drinking behaviour
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Viennalead
- Medical University of Viennacollaborator
- Queensland University of Technologycollaborator
- Flinders Universitycollaborator
- Edith Cowan Universitycollaborator
Study Sites (2)
Medical University of Vienna
Vienna, 1090, Austria
University of Vienna
Vienna, 1090, Austria
Related Publications (5)
Raubenheimer K, Hickey D, Leveritt M, Fassett R, Ortiz de Zevallos Munoz J, Allen JD, Briskey D, Parker TJ, Kerr G, Peake JM, Pecheniuk NM, Neubauer O. Acute Effects of Nitrate-Rich Beetroot Juice on Blood Pressure, Hemostasis and Vascular Inflammation Markers in Healthy Older Adults: A Randomized, Placebo-Controlled Crossover Study. Nutrients. 2017 Nov 22;9(11):1270. doi: 10.3390/nu9111270.
PMID: 29165355BACKGROUNDRaubenheimer K, Bondonno C, Blekkenhorst L, Wagner KH, Peake JM, Neubauer O. Effects of dietary nitrate on inflammation and immune function, and implications for cardiovascular health. Nutr Rev. 2019 Aug 1;77(8):584-599. doi: 10.1093/nutrit/nuz025.
PMID: 31150091BACKGROUNDBlekkenhorst LC, Bondonno NP, Liu AH, Ward NC, Prince RL, Lewis JR, Devine A, Croft KD, Hodgson JM, Bondonno CP. Nitrate, the oral microbiome, and cardiovascular health: a systematic literature review of human and animal studies. Am J Clin Nutr. 2018 Apr 1;107(4):504-522. doi: 10.1093/ajcn/nqx046.
PMID: 29635489BACKGROUNDFejes R, Pilat N, Lutnik M, Weisshaar S, Weijler AM, Kruger K, Draxler A, Bragagna L, Peake JM, Woodman RJ, Croft KD, Bondonno CP, Hodgson JM, Wagner KH, Wolzt M, Neubauer O. Effects of increased nitrate intake from beetroot juice on blood markers of oxidative stress and inflammation in older adults with hypertension. Free Radic Biol Med. 2024 Sep;222:519-530. doi: 10.1016/j.freeradbiomed.2024.07.004. Epub 2024 Jul 5.
PMID: 38972612DERIVEDFejes R, Lutnik M, Weisshaar S, Pilat N, Wagner KH, Stuger HP, Peake JM, Woodman RJ, Croft KD, Bondonno CP, Hodgson JM, Wolzt M, Neubauer O. Increased nitrate intake from beetroot juice over 4 weeks affects nitrate metabolism, but not vascular function or blood pressure in older adults with hypertension. Food Funct. 2024 Apr 22;15(8):4065-4078. doi: 10.1039/d3fo03749e.
PMID: 38546454DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Oliver Neubauer, Dr PhD, PD
University of Vienna
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- The two treatment arm will consist of a 4-week high-nitrate (HI-NI) intervention (using nitrate-rich beetroot juice) and a 4-week low-nitrate (LO-NI) intervention using nitrate-depleted beetroot juice as the placebo. All products will be obtained from the same supplier (James White Drinks Ltd., UK). The nitrate-depleted beetroot juice is generated for research purposes only. The two juices will be indistinguishable by taste, color, smell and packaging. The investigators involved in the data acquisition and analysis will be blind to the trial allocation until the study has been completed and all analyses have been performed.
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr PhD, PD
Study Record Dates
First Submitted
September 29, 2020
First Posted
October 14, 2020
Study Start
January 1, 2021
Primary Completion
March 28, 2023
Study Completion
March 28, 2023
Last Updated
May 10, 2023
Record last verified: 2023-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- The plan is to publish the findings in scientific journals and to present them at scientific meetings and to the public after the study is completed.
- Access Criteria
- Supporting the Open Access Policy of the University of Vienna, the PHAIDRA repository enables public access of the research data necessary to reproduce and to verify the results of publications from this research.
For long-time preservation and sharing of the research data, it is planned to use the PHAIDRA digital repository of the University of Vienna (https://phaidra.univie.ac.at). This repository enables the permanent secure storage of digital assists including open access publications and research data necessary to reproduce and to verify the results of the publications. For all publications and other data related to this research that will be made available, all of the individual participant data collected during the trial will be de-identified.